The new presidential administration also promised to significantly reduce business regulations, which also may be beneficial for small companies, as they are less equipped to deal with regulations and the expenses that ensue. Bruce Bittles, chief investment strategist at Robert W. Baird & Co. said, "Small-caps have been punished by overregulation because it is harder for them to absorb the impact of the regulation... Large companies are better equipped to deal with increased client costs, legal expenses."
Cell MedX Corp. (OTCQB: CMXC) is an early development stage bio-tech company focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness and alleviate complications associated with medical conditions including, but not limited to, diabetes, Parkinson's disease, high blood pressure.
Earlier this week Cell MedX Corp. announced that it has received an approval from Health Canada to commence its observational clinical trial in Canada. The company revealed that it will, "launch the observational clinical trial of its innovative and proprietary technology branded under the trade name eBalance. The intent of the Trial is to assess the impact of eBalance therapy as an adjunct treatment on HbA1c after three months of therapy in relation to the subject's baseline data and medical history. Additional objectives of the Trial will be to assess the effect of eBalance therapy on insulin resistance and sensitivity as well as on various complications caused by diabetes."
Chief Executive Officer and President of Cell MedX Corp. Frank McEnulty said in a statement, "I am very excited to receive the approval from Health Canada in that it allows us to further advance research of our eBalance technology as well as its effects on both diabetes and diabetic complications."
Pura Naturals Inc. (OTCQB: PNAT) launched a division focused on developing solutions using AirTech Foam technologies and allied products directed towards oil spill prevention and remediation in our waterways, known as the Pura Marine. Pura Marine is currently in negotiations with some of the largest marine oil transport companies in the United States and in addition is actively pursuing business in the trucking and oil sectors. "We are dedicated to focusing our proprietary technologies on industries and markets where we can provide better solutions for current challenges and unmet needs," said Derek Duhame, President of Pura Naturals, Inc.
Federal National Mortgage Association (OTCQB: FNMA) priced its first Multifamily DUS® REMIC in 2017 totaling $1.04 billion under its Fannie Mae Guaranteed Multifamily Structures program on January 18, 2017. "Agency CMBS has become a recognized asset class, led by Fannie Mae DUS MBS. We issued more than $55 billion in multifamily MBS last year, plus another $10 billion in GeMS new issuance - significantly more than any other securitized multifamily platform," said Josh Seiff, Fannie Mae's Vice President of Capital Markets and Trading. "FNA 2017-M1 continued the trend - more than 40 investors were involved in the deal, which included 111 loans and was just over $1.0 billion in size. We're looking forward to another market-leading year for the Fannie Mae DUS platform in 2017."
Paladin Energy Ltd (OTC: PALAF) is a uranium production company with projects currently in Australia and two mines in Africa with a strategy to become a major uranium mining house. Since 1998, during a period of sustained downturn in global uranium markets, Paladin accumulated a quality portfolio of advanced uranium projects each having production potential. The Langer Heinrich Mine in Namibia is Paladin's flagship project. The Company has completed a Stage 3 expansion and is now producing at a 5.2Mlb per annum rate. The Kayelekera Mine in Malawi, the Company's second mine, provided an excellent follow-up to Langer Heinrich.
In an upcoming clinical trial by biotech company, PharmaCyte Inc. (OTCQB: PMCB), will consist of patients who have inoperable pancreatic cancer that has not yet spread from the pancreas where it first started to any other place in the body. Patients must also have tumors that no longer respond to the combination chemotherapy treatment of Abraxane® plus gemcitabine after they've been on that treatment for a period of between 4 and 6 months. The company's new trial design calls for multiple cycles of ifosfamide to be given to those patients being treated with PharmaCyte's pancreatic cancer therapy. This will continue until the patients' tumors no longer respond to PharmaCyte's therapy or until treatment-related toxicity accumulates to unacceptable levels.
Please SIGN UP NOW at http://www.FinancialBuzz.com To Receive Alerts on Trending Financial News from all these companies. "The Latest Buzz in Financial News"
Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR branding, marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
For further information:
Media Contact: firstname.lastname@example.org , +1-877-601-1879